February 2026

UROLOGY

REFINING PROSTATE CANCER DETECTION THROUGH PROSTATE MRI

Prostate MRI is changing how clinicians decide when a biopsy is needed and how sampling is targeted to better detect clinically significant prostate cancer. In this episode of Better Edge, Hiten Patel, MD, discusses MRI‑informed risk stratification, including the use of an MRI‑based risk calculator, and how MRI‑targeted biopsy can reduce missed high‑grade disease. The episode also highlights how PSA density informs decision‑making after a negative MRI and how to manage discordant targeted and systematic biopsy results. Dr. Patel reviews lesion characteristics, like size and suspicion score, in the context of follow‑up and treatment intensity, along with emerging tools like PSMA PET and AI that may further refine detection and biopsy targeting.
Hiten Patel, MD, Assistant Professor of Urology at Northwestern Medicine ​

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like